Periodic Reporting for period 1 - MetaboMARKER (A metabolism-based prognostic biomarker for prostate cancer)
Période du rapport: 2017-06-01 au 2018-12-31
During the course of the proposal, we have performed a deep market analysis and have evaluated the best technology that could support the clinical application of the results obtained. We believe that this signature can provide unique clinical information about the aggressive features of prostate cancer, and, in turn, it could aid in the refinement of clinical guidelines for the treatment of this disease.